[l4CJaztreonam was admiistered intramuscularly (50 mg/kg) to male and female rats. Groups of 10 rats (five male and five female) were sacrificed at 0.25, 2, 6, and 24 h after dosing. Blood and various tissues were removed from six rats (three male and three female) in each group for determination of total radioactivity and unchanged aztreonam by liquid scintillation counting ahd thin-layer radi9chromatography. The remaining rats were prepared for whole-body autoradiography. Radioactivity was distributed rapidly to most tissues and was rapidly eliminated from blood into urine and bile. Concentrations of total radioactivity in kidney, liver, sinall and large intestines and their contents, and urinary bladder were,higher than those in serum at all the times examined. Concentrations of unchanged aztreonam in serum, kidney, liver, and lung declined at about the same rate as did that of total radioactivity ih the same tissues. The results of whole-body autoradiography essentially confirmed the results of the distribution of ['4C]aztreonam as determined by liquid scintillation counting. No major differences between males and females were observed when concentrations in organs common to both were compared.
common to both were compared.
Aztreonam is a novel, completely synthetic, monocyclic ,-lactam antimicrobial agent that is active against gramnegative bacteria (4) . Studies of the disposition of aztreonam in rats, dogs, and monkeys have beeh described previously (1) . The disposition and pharmacokinetics of aztreonam in humans have also been reported (3) .
The purpose of this study was to obtain data on the distribution of total radioactivity and unchanged aztreonam (selected tissues) in the tissues of male and female rats after single intramuscular doses of [l4C]aztreonam.
MATERIALS AND METHODS Compounds. [14C] aztreonam was synthesized at a specific activity of 8.5 ,uCi/mg, and the radiochemical purity, as determined by high-pressure liquid chromatography, was greater than 96% (2) . All other chemicals were obtained commercially.
Animals. Male and female CD outbred albino rats (Charles River Breeding Laboratories, Wilmington, Mass.), each weighing between 200 and 300 g, were housed in groups of four or five males or females in stainless steel cages. Rats were fasted beginning 24 h before dosing and continuing until the time of sacrifice, except for rats that were sacrificdd at 24 h after dose administration; these rats were fed ad libitum after 8 h. Water was available to all animals ad libitum.
Preparation and administration of the dose.
[l4C]aztreonam and nonradiolabeled aztreonam in a ratio of 1:1 (wt/wt) were dissolved in water (total, 50 mg/ml) along with an equimolar amount of L-arginine (40 mg/ml). removed from each of the six rats. Serum and protein-free filtrate were prepared from the blood samples for determination of protein binding; a previously described ultrafiltration procedure (2) was used. All samples were stoied at -12°C before analysis.
The remaining four rats (two male and two female) from each group were sacrificed by exposure to ether, frozen in a mixture of acetone and dry ice, and prepared for whole-body autoradiography.
Analysis of samples. Concentrations of total radioactivity in all tissue samples were determined by liquid scintillation couhting. Concentrations of unchanged aztreonam were determined in serum, intestinal contents, and selected tissues such as kidneys, liver, and lungs by methanolic extraction followed by thin-layer radiochromhtography.
Liquid scintillation counting. The procedure used for quantitating radioactivity has been described previously (1) . Individual samples were prepared as described below (all samples were analyzed in duplicate).
(i) Serum. A 0.1-inl Amount of serum was digested in 1.0 ml of a tissue solubilizer (Soluene-350; Packard Instrumnent Co., Downers Grove, Ill.), neutralized with 0.1 ml of a neutralizing solution (1) , and mixed with 15 ml of the scintillation cocktail. Protein-free filtrate (0.05 ml) was counted directly in 15 ml of the scintillation cocktail.
(ii) Tissue preparation by direct solubilization. The following tissues were completely solubilized by digestion before liquid scinitillation counting: adrenal gland, bone, bone marrow, brain, eye, heart, large intestine and its contents, lymph nodes, menitiges, muscle, ovary, pancreas, salivary gland, skin, small intestine and its contents, spleen, stomach, (iv) Methanolic extracts of tissues. Samples of methanolic extracts (1.0 ml) of serum and the kidneys, liver, and lungs were counted directly in 15 ml of the scintillation cocktail.
Extraction of serum and tissue samples. Serum samples (1 rml) were extracted three times with 3 ml of methanol, and 'z;
homogenates of liver, lungs, and kidneys (2 g) were extracted five times with 6 ml of methanol; aliquots (1.0 ml) of the combined methanolic extracts were assayed for total radioactivity. The remainder of each extract was filtered through glass wool and evaporated to dryness in vacuo at about 25°C.
The residue was reconstituted in 0.6 ml of methanol, and the radioactive components (unchanged aztreonam and its jQ metabolites) were quantified as described below. Thin-layer radiochromatography. The thin-layer radiochromatographic procedure has been reported separately in more detail (1) Because of the high variability in the stability data obtained, an accurate correction factor for degradation of aztreonam could not be determined from the spiked samples; hence, the concentrations of unchanged aztreonam in serum and tissue samples are reported uncorrected and represent minimum values.
Concentrations of total radioactivity. In general, there were no major differences between male and female rats with respect to the concentrations of total radioactivity in all tissues common to both sexes at any time point. In most tissues, concentrations of total radioactivity were highest at 0.25 h and then declined gradually to low, but still detectable, levels at 24 h after dosing. The detection limit was about 0.01 ,ug of aztreonam equivalents per ml. Semilogarithmic plots of the concentrations of total radioactivity versus time for serum and selected tissues are shown in Fig.   1 . Concentrations of total radioactivity in lungs and skin declined at about the same rate as those in the serum. The rate of decline of the radioactivity concentration was slower in the kidneys than in serum and faster in the liver than in serum.
When the results were expressed as ratios of the concentrations of total radioactivity in tissues to those in serum (Tables 1 and 2 ), it was clear that, for most tissues, concentrations of total radioactivity were lower than those in serum at all times. The following tissues showed mean concentrations of total radioactivity that were higher than those in serum at 24 h: kidneys, large intestine and its contents, liver, lymph nodes (females only), meninges, muscle (injection site), small intestine (females only) and its contents, stomach, and urinary bladder. That the concentrations of total radioactivity in most of these tissues were higher than those in serum is probably a consequence of their excretory role. The concentrations of total radioactivity in meninges were equal to or higher than those in serum at the later time points (6 and 24 h).
Concentrations of unchanged aztreonam. Concentrations of unchanged aztreonam were determined in selected tissues ( Table 3 ). The detection limit was about 0.01 ,uig/ml. There were no major differences between male and female rats with regard to the concentrations of unchanged aztreonam in these tissues. Between 6 and 24 h, concentrations of unchanged aztreonam in serum and liver declined at about the same rate, but those in kidneys and lungs declined at a somewhat slower rate (Fig. 2) .
Protein binding. The binding of radioactivity to serum proteins of male and female rats, as determined by ultrafiltration, ranged from an average of 65 to 94% for plasma samples at 0.25, 2, 6, and 24 h. Whole-body autoradiography. The whole-body autoradiographic results were essentially identical for male and female rats. For brevity, representative autoradiographs are shown only for female rats (see Fig. 3-5) ; dark areas indicate the presence of radioactivity.
The results of whole-body autoradiography essentially confirm the results of the distribution of [14C]aztreonam in various tissues as determined by liquid scintillation counting. After 0.25 h, radioactivity was widely distributed throughout the body and was present in high concentrations in organs well perfused with blood, especially liver, heart, lungs, and skin (Fig. 3) . Excretion of radioactivity commenced rapidly, as shown by the presence of radioactivity in the contents of the small intestine at 0.25 h. After 2 h, the concentrations in organs well perfused with blood were reduced and higher concentrations of radioactivity were seen in the contents of the small intestine, indicating continuation of excretion (Fig. 4) . The relative distribution of radioactivity at 6 h was similar to that observed at 24 h. At 24 h, small amounts of radioactivity were detected in the liver and kidneys and substantial amounts were detected in the contents of the large intestine (Fig. 5) . DISCUSSION After single intramuscular doses of [14C]aztreonam were given to male and female rats, the radioactivity was well distributed throughout the body and there was no evidence that total radioactivity tended to concentrate to any notable extent in individual tissues other than kidney, liver, and the gastrointestinal tract. That the concentrations of total radioactivity in these organs were generally higher than those in serum was attributed to their excretory role. For most tissues, the ratios of concentrations of total radioactivity in tissues to those in serum increased with time, indicating that the radioactivity was eliminated from the tissues at a slower rate than from serum. The higher concentrations of total radioactivity in meninges compared with those in serum at 6 and 24 h after administration of the dose suggest that Although concentrations of unchanged aztreonam were determined only in selected tissues, it is interesting to note that, at the later time points (6 and 24 h), the concentrations of aztreonam in these tissues were generally greater than those in serum. These data suggest that the elimination of aztreonam from the tissues appears to be somewhat slower than that from serum, and consequently, the duration of activity of aztreonam in many target tissues might be longer than that predicted on the basis of the rate of decline of aztreonam levels in serum.
